Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The user shared their experience with CB-03-01 (Breezula/Clascoterone) for hair loss, noting reduced shedding and improved hair appearance but experiencing significant sleep disturbances and low energy due to HPA axis suppression. They decided to stop using it due to these side effects and are waiting for GT20029 as an alternative.

The user experienced significant hair improvement after switching from topical to oral treatments, using finasteride, minoxidil, and biotin. They reported no major side effects, except for slightly thicker hair on their hands.

SCUBE3 and Amplifica's progress in hair loss treatment is being discussed, with inquiries about their current status and clinical trials. No specific updates or new information are provided in the conversation.

The conversation discusses using peptides BPC-157 and TB-500, combined with microneedling, to potentially enhance hair regrowth. The user plans to try BPC-157 due to its lower cost and reports of hair growth, despite limited human trials and concerns about side effects from other treatments like minoxidil and finasteride.

A user shared their experience using 2-deoxy-D-ribose (2dDR) for hair regrowth, noting early positive results without side effects, alongside their long-term use of minoxidil and finasteride. They mentioned 2dDR's potential effectiveness in boosting blood flow to hair follicles and its availability online.

The post discusses the user's experience with hair loss treatment RU58841, which was tested for quality and found to be 96+% pure. The conversation includes various responses, with some users questioning the safety of the product and others expressing satisfaction with the test results.

The conversation discusses a botanically derived treatment for androgenetic alopecia using ingredients like saw palmetto, green tea, and evening primrose, showing impressive results over 270 days. Concerns include the study's uncontrolled nature and potential product motivation, with suggestions to enhance absorption through derma rolling.

BPC-157 may promote hair growth by increasing angiogenesis, similar to how Minoxidil works, though no direct research confirms this yet. Users report combining BPC-157 with Minoxidil and finasteride for better results, but concerns about long-term safety exist.

The conversation is about hair loss treatments, specifically using finasteride, minoxidil, and biotin, with a focus on the effectiveness of Hims products. Users discuss the results, potential side effects, and the role of biotin in the treatment.

The user is considering using CB or clascoterone for hair loss, potentially as an alternative to RU. They're also contemplating asking a dermatologist for topical clascoterone cream to apply to their temple.

The user experienced reduced hair loss using an online serum but found it too expensive and is seeking a vendor for ptd-dbm. They are also interested in KY19382 but are unable to find it.

Creatine use with finasteride increased DHT levels, possibly affecting hair loss. The user plans to reduce creatine to stabilize DHT and hair shedding.

Twist-1 is being explored as a promising early-stage hair loss treatment, while Scube-3's effect on Twist-1 in breast cancer cells raises concerns about its use for hair loss. The conversation discusses the potential differences in protein effects across various cell types.

The conversation discusses the safety study of PP405, emphasizing that early trials focus on safety rather than efficacy, and that any efficacy data from such a short study should be viewed skeptically. It also highlights that the information released is primarily for securing funding, and that meaningful efficacy results are expected in later phases.

Injectable GHK-CU and BPC157 were discussed for hair loss, but users did not notice significant hair changes. BPC157 was noted to help with shoulder issues.

Breezula's phase 2 showed reduced efficacy after 6 months, but phase 3 had positive results, causing confusion about any changes made to the drug. There is frustration over the long timeline for hair loss treatments, with some users expressing more interest in other potential treatments like GT-20029.

RU58841 is absorbed systemically in humans, contradicting claims it stays local, but no harm is proven. Alternatives like CB-03-01 or KX-826, especially with finasteride, are suggested for safety.

The user has been taking oral Finasteride and topical Essengen 6 Plus for hair loss and is experiencing increased depression. They plan to get bloodwork to check hormone levels and are seeking advice on which tests to include.

Minoxidil was applied to a single miniaturized hair follicle over four months, resulting in less miniaturization but not yet terminal growth. The user used a 5% minoxidil solution, specifically the Regaine brand, and observed changes using a handheld WiFi microscope.

Finasteride, Minoxidil, Bioneer CosmeRNA, Technoderma, Kintor, Hope, Breezula, and Follicum treatments showed increases in hair count, with Technoderma showing the highest increase at 24.3 hairs/cm². Amplifica has not yet published results.

The conversation is about a female seeking advice on using bicalutamide for female pattern hair loss (FPHL) and considering switching from pumpkin seed oil pills to a stronger treatment. She is looking for dosage information to discuss with her dermatologist.

A user shared their baseline bloodwork results before starting Finasteride 1mg every other day, seeking comparison with others who have done similar tests. They are interested in any changes observed after beginning the treatment.

Oral PTD-DBM was discussed as a potential hair loss treatment, but it was deemed ineffective in humans despite promising results in mice. The conversation concluded that trying it without VPA might be unwise.

A user shared their 4-month progress using 2.5mg minoxidil, 1mg finasteride, and 10mg biotin, noting slight testicular discomfort initially but no significant hairline changes yet. Another user reported similar treatment results, with hair darkening at the scalp center and small temple hairs.

Longitudinal partial follicular unit transplantation involves extracting part of the donor follicular unit, allowing the donor area to maintain hair production and potentially increasing transplant yield. The conversation questions if this method is practiced in clinics or remains theoretical, and whether it relates to hair cloning or multiplication.

Botox injections may be more effective than finasteride for hair growth by reducing scalp tension. The discussion also suggests choosing FUE over FUT due to potential loss of scalp elasticity with FUT.

RU58841 shows the strongest results despite weaker binding affinity, while KX-826 and CB-03-01 are more expensive and have minimal side effects. RU58841 is considered effective but has potential health risks if ingested; users report positive outcomes with RU58841 and finasteride.

David Barreto shared that a London-based research group is conducting a 12-month trial for a new nutraceutical treatment for pattern hair loss, designed with Dr. Carlos Puig. The trial aims to provide robust data, with results expected in 1-2 years, potentially representing a significant advancement since finasteride’s introduction in 1997.

The conversation is about a user preparing to join the ABS-201 clinical trial for hair loss treatment, which involves a prolactin inhibitor. The user plans to update others on their progress if enrolled.

The conversation discusses a user experimenting with RU58841 for hair regrowth by ingesting it, which others find concerning. There are mentions of potential side effects and comparisons to other treatments like minoxidil, finasteride, and flutamide.